Criticare Systems announces patent award for Immtech International Inc.MILWAUKEE--(HealthWire)--Feb. 7, 1996--Criticare Systems Inc. (NASDAQ/NMS:CXIM), a manufacturer and marketer of medical monitoring equipment, today provided an update on Immtech International Inc., a biotechnology research company in which Criticare recently increased its ownership to 35 percent. Immtech's proprietary product, mCRP, is showing anticancer effects on primary and metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. tumors. Dr. Larry Potempa, director of immunobiochemistry and chief scientific officer at Immtech, announced that Immtech has recently been awarded a U.S. patent on the use of Immtech's proprietary mCRP protein to locate and strengthen body tissues damaged by cancer. The mCRP protein, naturally present in the body's normal fibrous tissues fibrous tissue n. Tissue composed of bundles of collagenous white fibers between which are rows of connective tissue cells. , gets consumed during processes of inflammation and disease progression. When mCRP is replaced, it helps the tissues reinforce their structure, making them more able to fight and resist the invasion of metastatic cancer Metastatic cancer A cancer that has spread to an organ or tissue from a primary cancer located elsewhere in the body. Mentioned in: Liver Cancer metastatic cancer cells or microorganisms. Immtech has shown that injected mCRP rapidly and specifically locates body sites with heightened immune activities, accelerating the natural replacement of what has been consumed in the body's natural defense response. Immtech's mCRP drug promises not only to be a drug therapy to strengthen the body's immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. , but could also turn out to be a powerful adjunctive therapy adjunctive therapy Medtalk A therapeutic maneuver(s) with an ancillary role in treating a disease by ↓ M&M, but not part of the immediate therapy required to stabilize the Pt. Cf Adjuvant therapy. enhancing other drugs while mitigating toxicity. Immtech also reported that it will have a manuscript published in the upcoming issue of Experimental Hematology describing the biological activities of mCRP as a therapeutic to boost platelet growth. This manuscript describes another important bioactivity bi·o·ac·tiv·i·ty n. The effect of a given agent, such as a vaccine, upon a living organism or on living tissue. of mCRP in helping the body maintain sufficient levels of platelets, cells critical to controlling bleeding and maintaining blood vessel blood vessel n. An elastic tubular channel, such as an artery, a vein, a sinus, or a capillary, through which the blood circulates. blood vessel(s), n the network of muscular tubes that carry blood. integrity. Criticare Systems Inc. designs, manufactures and markets cost-effective patient monitoring systems and noninvasive sensors for a wide range of hospital and alternate health care environments throughout the world. Its common stock is traded on NASDAQ's National Market System under the symbol "CXIM." CONTACT: Criticare Systems Inc., Milwaukee Gerhard Von der Ruhr, 414/798-8282 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion